Shots:

• The companies collaborated for Adagio’s ADG20 for both the treatment & prevention of COVID-19 as monothx. or combination regimen
• Biocon will gain rights to manufacture & commercialize ADG20 for COVID-19 in India and select emerging markets based on the commercial process developed for ADG20. The company will have the access to Adagio’s ongoing P-II/III study data & to its anticipated EUA along with regulatory submissions- supporting the approval or EUA in India & other emerging markets
• ADG20 is currently being evaluated in two studies. The STAMP trial to evaluate ADG20 for non-hospitalized COVID-19 patients and the EVADE trial to evaluate ADG20 for the prevention of COVID-19

  | Ref: Businesswire | Image: Adagio